John Foster

Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO.

InnerSpace Neuro Solutions, Inc. provides health care services. The company was founded in 2013 and is headquartered in Tustin, CA.

SpineThera, Inc. engages in the designs and development of injectable drugs to meet the requirements for administration in and near the spine. Its product include SX600, an investigational drug. The company was founded by Jeffrey Missling and is headquartered in Plymouth, MN.

SpineThera, Inc. engages in the designs and development of injectable drugs to meet the requirements for administration in and near the spine. Its product include SX600, an investigational drug. The company was founded by Jeffrey Missling and is headquartered in Plymouth, MN.

InnerSpace Neuro Solutions, Inc. provides health care services. The company was founded in 2013 and is headquartered in Tustin, CA.

SpineThera, Inc. engages in the designs and development of injectable drugs to meet the requirements for administration in and near the spine. Its product include SX600, an investigational drug. The company was founded by Jeffrey Missling and is headquartered in Plymouth, MN.

SpineThera, Inc. engages in the designs and development of injectable drugs to meet the requirements for administration in and near the spine. Its product include SX600, an investigational drug. The company was founded by Jeffrey Missling and is headquartered in Plymouth, MN.

Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO.